Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Sci Transl Med. 2023 Apr 19;15(692):eade4790. doi: 10.1126/scitranslmed.ade4790

Fig. 2. Mild solicited reactogenicity was reported after H1ssF vaccination.

Fig. 2.

Percentage of participants (x axis) reporting solicited local or systemic symptoms (y axis) in the 7 days after each H1ssF vaccination. For symptoms persisting more than 1 day, a single count per person at the maximum severity of the symptom was used for the figure. Pain/tenderness was the only local symptom reported; no swelling or redness was noted. There were also no reports of fever or joint pain. All reactogenicity was mild. N/A indicates that no boost vaccination was administered to the dose group.